Antibody Engineering
Engineered for stability and developability.
Optimized to reduce off-target uptake.
Designed for tumor-focused delivery.
PROTAC & Linker Design
Conjugate-optimized PROTAC payloads.
Stable antibody attachment in circulation.
Tumor-selective release by design.
Degrader Antibody Conjugate
Precision tumor targeting with degraders.
Antibody payload design built for safety.
Built to expand therapeutic index outcomes.
About us
Abmuno II is advancing Degrader Antibody Conjugates (DACs), a new therapeutic class that merges antibody precision with targeted protein degradation. We pursue only the most consequential opportunities, applying deliberate focus to programs with the greatest potential to be efficacious, safe, and clinically developable—aiming to deliver safer and more effective therapies.
Partnering
We partner with organizations committed to advancing innovative therapies.